This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (16)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jack Hirsh, MD; Mark Levine, MD, MSc

Arch Neurol. 1986;43(11):1162-1164.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Oral anticoagulant therapy is usually monitored by the one-stage prothrombin time (PT) (Quick-time). The PT result can be expressed as time in seconds, as a ratio (patient time in seconds/control time in seconds), as an index (which is control time/ patient time multiplied by 100), or as a percent of normal control plasma using a saline dilution curve. The guidelines for the optimal therapeutic range for the control of anticoagulant therapy have been debated for 40 years, and the recommendations have differed widely between experts. As a consequence, patients in North America are generally treated with higher doses of oral anticoagulants (and, therefore, exposed to a higher risk of bleeding) than their counterparts in the United Kingdom.

The main reason why patients in North America are treated with higher doses of oral anticoagulants is largely historic and related to the marked differences in sensitivity of the various PT reagents (thromboplastins) . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Medicine, McMaster University, Hamilton, Ontario.

Footnotes
Accepted for publication July 10, 1986.

Reprint requests to Department of Medicine, McMaster University, 1200 Main St W, Room 3W10, Hamilton, Ontario, Canada L8N 3Z5 (Dr Hirsh).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?